---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-071607"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:32:39.956387+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Oramed licenses oral insulin (ORMD-0801) to Medicox for South Korea; up to $18M milestones plus 15% royalties

## Summary
- Exclusive 10-year license for ORMD-0801 in South Korea.
- Up to $18M in developmental milestones; $2M already received.
- Up to 15% royalties on gross sales; Medicox funds regulatory approval.
- Medicox also pays transfer price per capsule; distribution targets agreed.

## SEC filing metadata
- accession: 0001213900-22-071607
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390022071607/0001213900-22-071607-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390022071607/ea168587-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-071607
- JSON: https://secwatch.observer/filing/0001213900-22-071607.json
- Plain text: https://secwatch.observer/filing/0001213900-22-071607.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.